Diagnosis

Henoch-Schönlein purpura

A benign self-limited small-vessel vasculitis characterized by purpura, arthritis, abdominal pain, and hematuria.

Also known as: IgA vasculitis

Etiology

Cause [aqs]

Pathophysiology [aqs]

  1. Mucous membranes of the salivary glands, lungs, and GI tract produce IgA

  2. Antigenic exposure (infection, drugs) --> triggers the formation of IgA-antibody immune complexes

  3. IgA complexes are deposited in the small vessels (usually capillaries) of the skin, joints, kidneys, and GI tract

  4. Proinflammatory mediators --> complement system activation:

    • Purpura and petechiae

    • Gastrointestinal hemorrhage

    • IgA nephropathy

Complications [qgi][aqs]

Epidemiology

Incidence per 100.000 [2is][syp][m8r][qgi][cwt][e98]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Anorexia, Aphasia, Arthralgia, Ataxia, Decreased consciousness, Diarrhea, Dysmenorrhea, Edema, Fatigue, Fever, Headache, Hematemesis, Hematochezia, Hematuria, Hepatomegaly, Melena, Nausea, Paresis, Seizure, Vomiting

Clinical findings

ANA, Bowel wall thickening, Elevated Creatinine, Elevated D-dimer, Elevated IgA, Elevated Sedimentation Rate, Eosinophilia, Leukocytosis, Proteinuria, Rheumatoid factor, Thrombocytosis

Anamneses

None listed.

Localized findings

Pain
Radiates
CaputAbdomenJoints
Pattern
Intermittent
Quality
Cramping
Severity
Mild (1-3)Moderate (4-7)
Rash
Radiates
ArmLower body
Distribution
MultipleSymmetric
Lesion type
BullaEcchymosesHematomaMaculePapulePetechiaPurpuraUlcerUrticariaVesicle
Color
Red
Associated symptom
Pain
Palpation
BlanchingPain
Swelling
Radiates
Scrotum
Onset
Acute (minutes)
Pattern
Constant

Approach

Diagnostic criteria [gn5][2is]

Treatment

Henoch-Schönlein purpura spontaneously resolves in 94 percent of children and 89 percent of adults. [qgi]

  1. Supportive treatment is the primary intervention

    • Rehydration with intravenous fluids

    • Pain management

    • Wound care for ulcerative skin lesions

  2. Immunsuppresion:

    • Oral prednisone (1-2 mg/kg daily for two weeks) if abdominal and joint symptoms

    • High-dose steroids + immunosuppressants if severe renal involvement [fzw][qeu]

      • Plasmapheresis

      • High-dose intravenous pulse methylprednisolone

      • Azathioprine

      • Cyclophosphamide

      • Mycophenolate mofetil

      • Cyclosporine A

      • Rituximab

      • Dapsone

  3. Proteinuria --> Angiotensin-converting enzyme inhibitors [aqs]

Differential diagnoses

Acute hemorrhagic edema of infancy, Acute pancreatitis, Appendicitis, Crohn disease, Disseminated intravascular coagulation, Encephalitis, Endocarditis, Epididymitis, Gastrointestinal obstruction, Glomerulonephritis, Hemolytic uremic syndrome, IgA nephropathy, Immune thrombocytopenic purpura, Intussusception, Meningitis, Polyarteritis nodosa, Renal failure, Rheumatic fever, Rocky mountain spotted fever, Systemic lupus erythematosus, Testicular torsion, Thrombotic thrombocytopenic purpura, Ulcerative colitis, Wegener's granulomatosis


References

[1] Roache-Robinson P, Killeen RB, Hotwagner DT. IgA Vasculitis (Henoch-Schönlein Purpura) [Updated 2023 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537252/

[2] Reamy BV, Williams PM, Lindsay TJ. Henoch-Schönlein purpura. Am Fam Physician. 2009 Oct 1;80(7):697-704.

[3] Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health. 2013 Dec;49(12):995-1003.

[4] Dolezalová P, Telekesová P, Nemcová D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol. 2004 Nov;31(11):2295-9.

[5] Lei WT, Tsai PL, Chu SH, Kao YH, Lin CY, Fang LC, Shyur SD, Lin YW, Wu SI. Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database. Pediatr Rheumatol Online J. 2018 Apr 16;16(1):25.

[6] Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002 Oct 19;360(9341):1197-202.

[7] Calviño MC, Llorca J, García-Porrúa C, Fernández-Iglesias JL, Rodriguez-Ledo P, González-Gay MA. Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine. 2001;80(5):279-290.

[8] Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010 May;69(5):798-806.

[9] Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999 Nov;78(6):395-409.

[10] Hetland LE, Susrud KS, Lindahl KH, Bygum A. Henoch-Schönlein Purpura: A Literature Review. Acta Derm Venereol. 2017 Nov 15;97(10):1160-1166.

[11] http://emedicine.medscape.com/article/984105 (2014-01-02); [Medscape]

[12] http://emedicine.medscape.com/article/780452 (2014-01-02); [Medscape]

[13] Penny K, Fleming M, Kazmierczak D, Thomas A. An epidemiological study of Henoch-Schönlein purpura. Paediatr Nurs. 2010 Dec;22(10):30-5.

Scroll to top